Brescia

• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended
  2024-514515-10-00 5 2016-06-16 Breast Cancer
• Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m … Ended
  2024-516630-35-01 4 2015-01-12 NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS
• ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER … Ended
  2024-511639-83-00 9 2014-09-01 Anaplastic Large T-cell Lymphoma ALK negative
• Clinical trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycyclin … Ended
  2024-513426-29-00 4 2013-03-19 Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (O
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended
  2022-500691-59-00 4 Alzheimer's disease (AD)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended
  2022-502233-25-00 5 Schizophrenia
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6) Ended
  2022-502268-18-00 5 Neurocognitive Disorders
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended
  2023-508700-38-00 4 Metastatic or locally advanced unresectable solid tumors progressing a
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended
  2024-515393-27-00 4 Nonsquamous non-small cell lung cancer
• AUSTRAL trial: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in st … Ended
  2024-515942-18-01 4 Stage III NSCLC patients with loco-regional relapse > 12 months from t
• A Phase II, open label, single arm, multicentre study on THOracic Radiotherapy in Extensive Stage SCLC patients submitted to first line CHT- … Ended
  2024-517445-13-00 4 Extended stage small cell lung cancer patients confirmed histologicall
• Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle … Ended
  2025-520735-16-00 4 CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

Showing 529–546 of 546 trials